Kinetics of drug action in disease states: towards physiology-based pharmacodynamic (PBPD) models

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 42, Issue 5, 2015, Pages 447-462

  Danhof, Meindert ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Biophase distribution; Disease systems analysis; Dynamical systems analysis; Receptor theory

Indexed keywords

DISEASES; DRUG ACTIVATION; DRUG BINDING; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG TARGETING; DRUG TOLERANCE; ENANTIOMER; HOMEOSTASIS; HUMAN; METABOLITE; NONHUMAN; PHARMACODYNAMIC PARAMETERS; PHARMACOKINETICS; PRIORITY JOURNAL; REVIEW; SYSTEM ANALYSIS; SYSTEMATIC REVIEW (TOPIC); BIOLOGICAL MODEL; DRUG THERAPY; KINETICS; METABOLISM; THEORETICAL MODEL;

DRUG;

DISEASE; DRUG THERAPY; KINETICS; MODELS, BIOLOGICAL; MODELS, THEORETICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

EID: 84942505656     PISSN: 1567567X     EISSN: 15738744     Source Type: Journal    
DOI: 10.1007/s10928-015-9437-x     Document Type: Review

References (123)

1. Kato R (1977) Drug metabolism under pathological and abnormal physiological states in animals and man. Xenobiotica 7(1–2):25–92
2. Koch-Weser J (1972) Drug therapy. serum drug concentrations as therapeutic guides. N Engl J Med 287(5):227–231. doi:10.1056/NEJM197208032870505
3. Levy G (1974) Clinical pharmacokinetics. Academy of Pharmaceutical Sciences, Washington
4. Evans WES, Jerome J, Jusko WJ (1980) Applied pharmacokinetics: principles of therapeutic drug monitoring. Applied Therapeutics Inc., San Francisco, vol 3. Biopharmaceutics & Drug Disposition, Wiley. doi:10.1002/bdd.2510030315
5. Danhof M, Levy G (1984) Kinetics of drug action in disease states. I. Effect of infusion rate on phenobarbital concentrations in serum, brain and cerebrospinal fluid of normal rats at onset of loss of righting reflex. J Pharmacol Exp Ther 229(1):44–50
6. Levy G (1966) Kinetics of pharmacologic effects. Clin Pharmacol Ther 7(3):362–372
7. Nagashima R, O’Reilly RA, Levy G (1969) Kinetics of pharmacologic effects in man: the anticoagulant action of warfarin. Clin Pharmacol Ther 10(1):22–35
8. Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J (1979) Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 25(3):358–371
9. Gibaldi M, Levy G, Hayton W (1972) Kinetics of the elimination and neuromuscular blocking effect of d-tubocurarine in man. Anesthesiology 36(3):213–218
10. Hisaoka M, Levy G (1985) Effect of pregnancy on ethanol concentrations at onset of loss of righting reflex in rats. Pediatr Pharmacol (New York) 5(1):1–5
11. Klockowski PM, Levy G (1988) Kinetics of drug action in disease states. XXIV. Pharmacodynamics of diazepam and its active metabolites in rats. J Pharmacol Exp Ther 244(3):912–918
12. Walker JS, Klockowski PM, Levy G (1989) Kinetics of drug action in disease states. XXXI. Effect of experimental hyperthyroidism on the hypnotic activity of a benzodiazepine (oxazepam) in rats. Pharm Res 6(5):404–407
13. Yasuhara M, Levy G (1988) Kinetics of drug action in disease states. XXVII. Effect of experimental renal failure on the pharmacodynamics of zoxazolamine and chlorzoxazone. J Pharmacol Exp Ther 246(1):165–169
14. Morris ME, Levy G (1985) Pharmacodynamics of the hypnotic effect of salicylamide in rats. J Pharm Sci 74(6):599–602
15. Ramzan IM, Levy G (1986) Kinetics of drug action in disease states. XVI. Pharmacodynamics of theophylline-induced seizures in rats. J Pharmacol Exp Ther 236(3):708–713
16. Ramzan I, Levy G (1989) Kinetics of drug action in disease states. XXXIII: disparate effects of pentylenetetrazol in rats as a function of renal disease model and pharmacologic endpoint. J Pharm Sci 78(2):142–145
17. Hatanaka T, Sato S, Endoh M, Katayama K, Kakemi M, Koizumi T (1988) Effect of chlorpromazine on the pharmacokinetics and pharmacodynamics of pentobarbital in rats. J Pharmacobiodyn 11(1):18–30
18. Patsalos PN, Alavijeh MS, Semba J, Lolin YI (1992) A freely moving and behaving rat model for the chronic and simultaneous study of drug pharmacokinetics (blood) and neuropharmacokinetics (cerebrospinal fluid): hematological and biochemical characterization and kinetic evaluation using carbamazepine. J Pharmacol Toxicol Methods 28(1):21–28
19. Dutta S, Matsumoto Y, Gothgen NU, Ebling WF (1997) Concentration-EEG effect relationship of propofol in rats. J Pharm Sci 86(1):37–43. doi:10.1021/js960247n
20. Sato S, Koshiro A (1995) Pharmacokinetic analysis of chlorpromazine in rat serum, cerebrospinal fluid and striatum. Biol Pharm Bull 18(4):593–599
21. Cadart M, Marchand S, Pariat C, Bouquet S, Couet W (2002) Ignoring pharmacokinetics may lead to isoboles misinterpretation: illustration with the norfloxacin-theophylline convulsant interaction in rats. Pharm Res 19(2):209–214
22. de Lange EC (2013) Utility of CSF in translational neuroscience. J Pharmacokinet Pharmacodyn 40(3):315–326. doi:10.1007/s10928-013-9301-9
23. Zuideveld KP, Treijtel N, Van der Graaf PH, Danhof M (2000) Enantioselective high-performance liquid chromatographic analysis of the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin. Application to a pharmacokinetic-pharmacodynamic study in rats. J Chromatogr B Biomed Sci Appl 738(1):67–73
24. Danhof M, Levy G (1985) Kinetics of drug action in disease states. V. Acute effect of urea infusion on phenobarbital concentrations in rats at onset of loss of righting reflex. J Pharmacol Exp Ther 232(2):430–434
25. Dingemanse J, Thomassen D, Mentink BH, Danhof M (1988) Strategy to assess the role of (inter)active metabolites in pharmacodynamic studies in vivo: a model study with heptabarbital. J Pharm Pharmacol 40(8):552–557
26. Holford NH, Coates PE, Guentert TW, Riegelman S, Sheiner LB (1981) The effect of quinidine and its metabolites on the electrocardiogram and systolic time intervals: concentration–effect relationships. Br J Clin Pharmacol 11(2):187–195
27. Asthana OP, Woodcock BG, Wenchel M, Fromming KH, Schwabe L, Rietbrock N (1984) Verapamil disposition and effect on PQ-intervals after buccal, oral and intravenous administration. Arzneimittelforschung 34(4):498–502
28. Johnston A, Burgess CD, Hamer J (1981) Systemic availability of oral verapamil and effect on PR interval in man. Br J Clin Pharmacol 12(3):397–400
29. Mandema JW, Tukker E, Danhof M (1991) Pharmacokinetic-pharmacodynamic modelling of the EEG effects of midazolam in individual rats: influence of rate and route of administration. Br J Pharmacol 102(3):663–668
30. Cox EH, Kuipers JA, Danhof M (1998) Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats: assessment of rapid functional adaptation. Br J Pharmacol 124(7):1534–1540. doi:10.1038/sj.bjp.0701972
31. Mathot RA, van Schaick EA, Langemeijer MW, Soudijn W, Breimer DD, Ijzerman AP, Danhof M (1994) Pharmacokinetic-pharmacodynamic relationship of the cardiovascular effects of adenosine A1 receptor agonist N6-cyclopentyladenosine in the rat. J Pharmacol Exp Ther 268(2):616–624
32. Klockowski PM, Levy G (1987) Kinetics of drug action in disease states. XXI. Relationship between drug infusion rate and dose required to produce a pharmacologic effect. J Pharm Sci 76(7):516–520
33. Maynert EW, Klingman GI (1962) Tolerance to morphine. I. Effects on catecholamines in the brain and adrenal glands. J Pharmacol Exp Ther 135:285–295
34. Ramzan IM, Levy G (1985) Kinetics of drug action in disease states. XIV. Effect of infusion rate on pentylenetetrazol concentrations in serum, brain and cerebrospinal fluid of rats at onset of convulsions. J Pharmacol Exp Ther 234(3):624–628
35. Danhof M, Hisaoka M, Levy G (1984) Kinetics of drug action in disease states. II. Effect of experimental renal dysfunction on phenobarbital concentrations in rats at onset of loss of righting reflect. J Pharmacol Exp Ther 230(3):627–631
36. Hisaoka M, Danhof M, Levy G (1985) Kinetics of drug action in disease states. VII. Effect of experimental renal dysfunction on the pharmacodynamics of ethanol in rats. J Pharmacol Exp Ther 232(3):717–721
37. Ramzan IM, Levy G (1987) Kinetics of drug action in disease states. XVIII. Effect of experimental renal failure on the pharmacodynamics of theophylline-induced seizures in rats. J Pharmacol Exp Ther 240(2):584–588
38. Keane PE, Biziere K (1987) The effects of general anaesthetics on GABAergic synaptic transmission. Life Sci 41(12):1437–1448
39. Hevers W, Luddens H (1998) The diversity of GABAA receptors. Pharmacological and electrophysiological properties of GABAA channel subtypes. Mol Neurobiol 18(1):35–86. doi:10.1007/BF02741459
40. Greenberg DA, Cooper EC, Gordon A, Diamond I (1984) Ethanol and the gamma-aminobutyric acid-benzodiazepine receptor complex. J Neurochem 42(4):1062–1068
41. Dingemanse J, Polhuijs M, Danhof M (1988) Altered pharmacokinetic-pharmacodynamic relationship of heptabarbital in experimental renal failure in rats. J Pharmacol Exp Ther 246(1):371–376
42. Hisaoka M, Levy G (1985) Kinetics of drug action in disease states. XIII. Effect of dialyzable component(s) of uremic blood on phenobarbital concentrations in rats at onset of loss of righting reflex. J Pharmacol Exp Ther 234(1):180–183
43. Hoffman A, Levy G (1989) Kinetics of drug action in disease states. XXIX. Effect of experimental nephrotic syndrome on the pharmacodynamics of heptabarbital: implications of severe hypoalbuminemia. J Pharmacol Exp Ther 249(1):117–122
44. Barnes PJ (2013) Theophylline. Am J Respir Crit Care Med 188(8):901–906. doi:10.1164/rccm.201302-0388PP
45. Paloucek FP, Rodvold KA (1988) Evaluation of theophylline overdoses and toxicities. Ann Emerg Med 17(2):135–144
46. Jones HM, Rowland-Yeo K (2013) Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and developmen. CPT: Pharm Syst Pharmacol 2(8):1–12
47. Rowland M, Lesko LJ, Rostami-Hodjegan A (2015) Physiologically based pharmacokinetics is impacting drug development and regulatory decision making. CPT: Pharm Syst Pharmacol 4(6):313–315
48. Dingemanse J, Hutson PH, Langemeijer MW, Curzon G, Danhof M (1988) Application of serial sampling of cerebrospinal fluid in pharmacodynamic studies with a drug active in the CNS: heptabarbital concentrations at onset and offset of loss of righting reflex in rats. Neuropharmacology 27(5):467–474
49. van Bree JB, Tio S, de Boer AG, Danhof M, Verhoef JC, Breimer DD (1990) Transport of desglycinamide-arginine vasopressin across the blood-brain barrier in rats as evaluated by the unit impulse response methodology. Pharm Res 7(3):293–298
50. van Bree JB, Baljet AV, van Geyt A, de Boer AG, Danhof M, Breimer DD (1989) The unit impulse response procedure for the pharmacokinetic evaluation of drug entry into the central nervous system. J Pharmacokinet Biopharm 17(4):441–462
51. van Bree JB, Heijligers-Feijen CD, de Boer AG, Danhof M, Breimer DD (1991) Stereoselective transport of baclofen across the blood-brain barrier in rats as determined by the unit impulse response methodology. Pharm Res 8(2):259–262
52. Mandema JW, Heijligers-Feijen CD, Tukker E, De Boer AG, Danhof M (1992) Modeling of the effect site equilibration kinetics and pharmacodynamics of racemic baclofen and its enantiomers using quantitative EEG effect measures. J Pharmacol Exp Ther 261(1):88–95
53. de Lange EC, Danhof M (2002) Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain. Clin Pharmacokinet 41(10):691–703. doi:10.2165/00003088-200241100-00001
54. Groenendaal D, Freijer J, de Mik D, Bouw MR, Danhof M, de Lange EC (2007) Population pharmacokinetic modelling of non-linear brain distribution of morphine: influence of active saturable influx and P-glycoprotein mediated efflux. Br J Pharmacol 151(5):701–712. doi:10.1038/sj.bjp.0707257
55. Westerhout J, Smeets J, Danhof M, de Lange EC (2013) The impact of P-gp functionality on non-steady state relationships between CSF and brain extracellular fluid. J Pharmacokinet Pharmacodyn 40(3):327–342. doi:10.1007/s10928-013-9314-4
56. Letrent SP, Pollack GM, Brouwer KR, Brouwer KL (1998) Effect of GF120918, a potent P-glycoprotein inhibitor, on morphine pharmacokinetics and pharmacodynamics in the rat. Pharm Res 15(4):599–605
57. Westerhout J, Ploeger B, Smeets J, Danhof M, de Lange EC (2012) Physiologically based pharmacokinetic modeling to investigate regional brain distribution kinetics in rats. AAPS J 14(3):543–553. doi:10.1208/s12248-012-9366-1
58. Westerhout J, van den Berg DJ, Hartman R, Danhof M, de Lange EC (2014) Prediction of methotrexate CNS distribution in different species—influence of disease conditions. Eur J Pharm Sci 57:11–24. doi:10.1016/j.ejps.2013.12.020
59. Dingemanse J, Danhof M, Breimer DD (1988) Pharmacokinetic-pharmacodynamic modeling of CNS drug effects: an overview. Pharmacol Ther 38(1):1–52
60. Visser SA, Smulders CJ, Reijers BP, Van der Graaf PH, Peletier LA, Danhof M (2002) Mechanism-based pharmacokinetic-pharmacodynamic modeling of concentration-dependent hysteresis and biphasic electroencephalogram effects of alphaxalone in rats. J Pharmacol Exp Ther 302(3):1158–1167
61. Stevens J, Ploeger BA, Hammarlund-Udenaes M, Osswald G, van der Graaf PH, Danhof M, de Lange EC (2012) Mechanism-based PK-PD model for the prolactin biological system response following an acute dopamine inhibition challenge: quantitative extrapolation to humans. J Pharmacokinet Pharmacodyn 39(5):463–477. doi:10.1007/s10928-012-9262-4
62. Zuideveld KP, Rusic-Pavletic J, Maas HJ, Peletier LA, Van der Graaf PH, Danhof M (2002) Pharmacokinetic-pharmacodynamic modeling of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine in rats. J Pharmacol Exp Ther 303(3):1130–1137. doi:10.1124/jpet.102.036798
63. Tuk B, van Oostenbruggen MF, Herben VM, Mandema JW, Danhof M (1999) Characterization of the pharmacodynamic interaction between parent drug and active metabolite in vivo: midazolam and alpha-OH-midazolam. J Pharmacol Exp Ther 289(2):1067–1074
64. Zuideveld KP, Van der Graaf PH, Newgreen D, Thurlow R, Petty N, Jordan P, Peletier LA, Danhof M (2004) Mechanism-based pharmacokinetic-pharmacodynamic modeling of 5-HT1A receptor agonists: estimation of in vivo affinity and intrinsic efficacy on body temperature in rats. J Pharmacol Exp Ther 308(3):1012–1020. doi:10.1124/jpet.103.059030
65. Ploeger BA, van der Graaf PH, Danhof M (2009) Incorporating receptor theory in mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling. Drug Metab Pharmacokinet 24(1):3–15
66. Visser SA, Wolters FL, Gubbens-Stibbe JM, Tukker E, Van Der Graaf PH, Peletier LA, Danhof M (2003) Mechanism-based pharmacokinetic/pharmacodynamic modeling of the electroencephalogram effects of GABAA receptor modulators: in vitro-in vivo correlations. J Pharmacol Exp Ther 304(1):88–101. doi:10.1124/jpet.102.042341
67. Van der Graaf PH, Danhof M (1997) Analysis of drug-receptor interactions in vivo: a new approach in pharmacokinetic-pharmacodynamic modelling. Int J Clin Pharmacol Ther 35(10):442–446
68. Cox EH, Kerbusch T, Van der Graaf PH, Danhof M (1998) Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. J Pharmacol Exp Ther 284(3):1095–1103
69. van der Sandt IC, Smolders R, Nabulsi L, Zuideveld KP, de Boer AG, Breimer DD (2001) Active efflux of the 5-HT(1A) receptor agonist flesinoxan via P-glycoprotein at the blood-brain barrier. Eur J Pharm Sci 14(1):81–86
70. Van der Graaf PH, Van Schaick EA, Visser SA, De Greef HJ, Ijzerman AP, Danhof M (1999) Mechanism-based pharmacokinetic-pharmacodynamic modeling of antilipolytic effects of adenosine A(1) receptor agonists in rats: prediction of tissue-dependent efficacy in vivo. J Pharmacol Exp Ther 290(2):702–709
71. Yassen A, Olofsen E, Kan J, Dahan A, Danhof M (2008) Pharmacokinetic-pharmacodynamic modeling of the effectiveness and safety of buprenorphine and fentanyl in rats. Pharm Res 25(1):183–193. doi:10.1007/s11095-007-9440-z
72. Yassen A, Olofsen E, Romberg R, Sarton E, Danhof M, Dahan A (2006) Mechanism-based pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine in healthy volunteers. Anesthesiology 104(6):1232–1242
73. Cox EH, Langemeijer MW, Gubbens-Stibbe JM, Muir KT, Danhof M (1999) The comparative pharmacodynamics of remifentanil and its metabolite, GR90291, in a rat electroencephalographic model. Anesthesiology 90(2):535–544
74. Garrido M, Gubbens-Stibbe J, Tukker E, Cox E, von Frijtag J, Kunzel D, Ij A, Danhof M, van der Graaf PH (2000) Pharmacokinetic-pharmacodynamic analysis of the EEG effect of alfentanil in rats following beta-funaltrexamine-induced mu-opioid receptor “knockdown” in vivo. Pharm Res 17(6):653–659
75. Danhof M, de Jongh J, De Lange EC, Della Pasqua O, Ploeger BA, Voskuyl RA (2007) Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. Ann Rev Pharmacol Toxicol 47:357–400. doi:10.1146/annurev.pharmtox.47.120505.105154
76. Kleinbloesem CH, van Brummelen P, Breimer DD (1987) Nifedipine. relationship between pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 12(1):12–29. doi:10.2165/00003088-198712010-00002
77. Bauer JA, Fung HL (1994) Pharmacodynamic models of nitroglycerin-induced hemodynamic tolerance in experimental heart failure. Pharm Res 11(6):816–823
78. Dayneka NL, Garg V, Jusko WJ (1993) Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 21(4):457–478
79. Jusko WJ (1995) Pharmacokinetics and receptor-mediated pharmacodynamics of corticosteroids. Toxicology 102(1–2):189–196
80. Jusko WJ, Ko HC (1994) Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin Pharmacol Ther 56(4):406–419
81. Sharma A, Ebling WF, Jusko WJ (1998) Precursor-dependent indirect pharmacodynamic response model for tolerance and rebound phenomena. J Pharm Sci 87(12):1577–1584
82. Ramakrishnan R, DuBois DC, Almon RR, Pyszczynski NA, Jusko WJ (2002) Fifth-generation model for corticosteroid pharmacodynamics: application to steady-state receptor down-regulation and enzyme induction patterns during seven-day continuous infusion of methylprednisolone in rats. J Pharmacokinet Pharmacodyn 29(1):1–24
83. Zuideveld KP, Van der Graaf PH, Peletier LA, Danhof M (2007) Allometric scaling of pharmacodynamic responses: application to 5-Ht1A receptor mediated responses from rat to man. Pharm Res 24(11):2031–2039. doi:10.1007/s11095-007-9336-y
84. Danhof M, de Lange EC, Della Pasqua OE, Ploeger BA, Voskuyl RA (2008) Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research. Trends Pharmacol Sci 29(4):186–191. doi:10.1016/j.tips.2008.01.007
85. Holford N (2015) Clinical pharmacology = disease progression + drug action. Br J Clin Pharmacol 79(1):18–27. doi:10.1111/bcp.12170
86. Holford N (2013) Disease progression and neuroscience. J Pharmacokinet Pharmacodyn 40(3):369–376. doi:10.1007/s10928-013-9316-2
87. Chan PL, Holford NH (2001) Drug treatment effects on disease progression. Ann Rev Pharmacol Toxicol 41:625–659. doi:10.1146/annurev.pharmtox.41.1.625
88. Post TM, Schmidt S, Peletier LA, de Greef R, Kerbusch T, Danhof M (2013) Application of a mechanism-based disease systems model for osteoporosis to clinical data. J Pharmacokinet Pharmacodyn 40(2):143–156. doi:10.1007/s10928-012-9294-9
89. Schmidt S, Post TM, Peletier LA, Boroujerdi MA, Danhof M (2011) Coping with time scales in disease systems analysis: application to bone remodeling. J Pharmacokinet Pharmacodyn 38(6):873–900. doi:10.1007/s10928-011-9224-2
90. de Winter W, DeJongh J, Post T, Ploeger B, Urquhart R, Moules I, Eckland D, Danhof M (2006) A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying type 2 diabetes mellitus. J Pharmacokinet Pharmacodyn 33(3):313–343. doi:10.1007/s10928-006-9008-2
91. Hoffman A, Klockowski PM, Levy G (1993) Kinetics of drug action in disease states. XLII. Effect of repeated blood sampling on the pharmacodynamics of phenobarbital in rats. J Pharm Sci 82(2):229–230
92. Ramzan IM, Levy G (1986) Chronic theophylline administration has no apparent effect on theophylline concentrations required to produce seizures in rats. Proc Soc Exp Biol Med 182(2):176–180
93. Danhof M, Levy G (1985) Kinetics of drug action in disease states. IV. Effect of pregnancy on phenobarbital concentrations at onset of loss of righting reflex in rats. J Pharmacol Exp Ther 232(2):426–429
94. Chou RC, Levy G (1984) Kinetics of drug action in disease states III: effect of pregnancy on the relationship between phenytoin concentration and antiseizure activity in rats. J Pharm Sci 73(10):1348–1351
95. Hisaoka M, Levy G (1985) Kinetics of drug action in disease states. IX. Effect of experimental fever on phenobarbital concentrations at onset of loss of righting reflex in rats. J Pharmacol Exp Ther 232(3):722–724
96. Yasuhara M, Levy G (1988) Kinetics of drug action in disease states. XXVI: effect of fever on the pharmacodynamics of theophylline-induced seizures in rats. J Pharm Sci 77(7):569–570
97. Walker JS, Levy G (1991) Kinetics of drug action in disease states. XXXVIII: effect of body temperature on the convulsant activity of pentylenetetrazol in rats. J Pharm Sci 80(10):928–930
98. Klockowski PM, Levy G (1988) Kinetics of drug action in disease states. XXIII: effect of acute hypovolemia on the pharmacodynamics of phenobarbital in rats. J Pharm Sci 77(4):365–366
99. Klockowski PM, Levy G (1988) Kinetics of drug action in disease states. XXV. Effect of experimental hypovolemia on the pharmacodynamics and pharmacokinetics of desmethyldiazepam. J Pharmacol Exp Ther 245(2):508–512
100. Sato S, Levy G (1989) Kinetics of drug action in disease states. XXXV: effect of hypovolemia on the pharmacodynamics of zoxazolamine in rats. J Pharm Sci 78(9):785–786
101. Yasuhara M, Levy G (1988) Kinetics of drug action in disease states XXVIII: effect of acute hypovolemia on theophylline-induced neurotoxicity in rats. J Pharm Sci 77(8):729–730
102. Wanwimolruk S, Levy G (1987) Kinetics of drug action in disease states. XX. Effects of acute starvation on the pharmacodynamics of phenobarbital, ethanol and pentylenetetrazol in rats and effects of refeeding and diet composition. J Pharmacol Exp Ther 242(1):166–172
103. Zhi JG, Levy G (1989) Kinetics of drug action in disease states. XXXVII. Effects of acute fluid overload and water deprivation on the hypnotic activity of phenobarbital and the neurotoxicity of theophylline in rats. J Pharmacol Exp Ther 251(3):827–832
104. Hoffman A, Levy G (1993) Kinetics of drug action in disease states. XLI. Effect of adrenalectomy on the hypnotic activity of phenobarbital, the neurotoxicity of theophylline and pain sensitivity in rats. J Pharmacol Exp Ther 264(2):859–862
105. Hisaoka M, Levy G (1985) Kinetics of drug action in disease states XI: effect of nicotine on the pharmacodynamics and pharmacokinetics of phenobarbital and ethanol in rats. J Pharm Sci 74(4):412–415
106. Hoffman A, Levy G (1990) Kinetics of drug action in disease states. XXXVI: effect of cyclosporine on the pharmacodynamics and pharmacokinetics of a barbiturate (heptabarbital) in rats. J Pharm Sci 79(1):19–22
107. Wilson TC, Levy G (1994) Kinetics of drug action in disease states. XLIII: potentiating effect of l-tryptophan on the hypnotic action of phenobarbital and ethanol in rats. J Pharm Sci 83(10):1433–1436
108. Wanwimolruk S, Levy G (1987) Kinetics of drug action in disease states. XXII. Effects of contraceptive steroids on the pharmacodynamics of ethanol in rats. Pharm Res 4(3):240–243
109. Hoffman A, Levy G (1990) Kinetics of drug action in disease states. XXXIX. Effect of orally administered activated charcoal on the hypnotic activity of phenobarbital and the neurotoxicity of theophylline administered intravenously to rats with renal failure. Pharm Res 7(3):242–246
110. Danhof M, Hisaoka M, Levy G (1985) Kinetics of drug action in disease states XII: effect of experimental liver diseases on the pharmacodynamics of phenobarbital and ethanol in rats. J Pharm Sci 74(3):321–324
111. Levy G (1994) Effect of hepatic cirrhosis on the pharmacodynamics and pharmacokinetics of mivacurium in humans. Pharm Res 11(5):772–773
112. Ramzan IM, Yasuhara M, Levy G (1987) Kinetics of drug action in disease states. XIX. Effect of experimental liver disease on the neurotoxicity of theophylline in rats. J Pharmacol Exp Ther 241(1):236–238
113. Danhof M, Hisaoka M, Levy G (1985) Kinetics of drug action in disease states. VI. Effect of experimental diabetes on phenobarbital concentrations in rats at onset of loss of righting reflex. J Pharmacol Exp Ther 232(2):435–438
114. Walker JS, Levy G (1989) Kinetics of drug action in disease states. XXXII: effect of experimental hypertension on the pharmacodynamics of phenobarbital in rats. J Pharm Sci 78(9):742–744
115. Walker JS, Levy G (1989) Kinetics of drug action in disease states. XXXIV. Effect of experimental thyroid disorders on the pharmacodynamics of phenobarbital, ethanol and pentylenetetrazol. J Pharmacol Exp Ther 249(1):6–10
116. Wilson TC, Levy G (1994) Kinetics of drug action in disease states. 45. Effect of elevated plasma creatinine concentrations on the hypnotic action of phenobarbital in normal rats. J Pharm Sci 83(6):913–914
117. Hoffman A, Levy G (1991) Kinetics of drug action in disease states. XL. Effect of the dialyzable component(s) of uremic blood on theophylline neurotoxicity in rats. Pharm Res 8(3):415–417
118. van Schaick EA, Kulkarni C, Kunzel JKFD, Mathot RA, Cristalli G, Ij AP, Danhof M (1997) Time course of action of three adenosine A1 receptor agonists with differing lipophilicity in rats: comparison of pharmacokinetic, haemodynamic and EEG effects. Naunyn Schmiedebergs Arch Pharmacol 356(6):827–837
119. Cox EH, Van Hemert JG, Tukker EJ, Danhof M (1997) Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats. J Pharmacol Toxicol Methods 38(2):99–108
120. Groenendaal D, Freijer J, Rosier A, de Mik D, Nicholls G, Hersey A, Ayrton AD, Danhof M, de Lange EC (2008) Pharmacokinetic/pharmacodynamic modelling of the EEG effects of opioids: the role of complex biophase distribution kinetics. Eur J Pharm Sci 34(2–3):149–163. doi:10.1016/j.ejps.2008.03.003
121. Yassen A, Kan J, Olofsen E, Suidgeest E, Dahan A, Danhof M (2006) Mechanism-based pharmacokinetic-pharmacodynamic modeling of the respiratory-depressant effect of buprenorphine and fentanyl in rats. J Pharmacol Exp Ther 319(2):682–692. doi:10.1124/jpet.106.107953
122. Johnson M, Kozielska M, Pilla Reddy V, Vermeulen A, Barton HA, Grimwood S, de Greef R, Groothuis GM, Danhof M, Proost JH (2014) Dopamine D2 receptor occupancy as a predictor of catalepsy in rats: a pharmacokinetic-pharmacodynamic modeling approach. Pharm Res 31(10):2605–2617. doi:10.1007/s11095-014-1358-7
123. Johnson M, Kozielska M, Pilla Reddy V, Vermeulen A, Li C, Grimwood S, de Greef R, Groothuis GM, Danhof M, Proost JH (2011) Mechanism-based pharmacokinetic-pharmacodynamic modeling of the dopamine D2 receptor occupancy of olanzapine in rats. Pharm Res 28(10):2490–2504. doi:10.1007/s11095-011-0477-7